文献速递肺结节与肺癌呼吸危重症与机械通气

晚期非小细胞肺癌免疫检查点抑制剂相关肌炎的临床与病理特征

[Clinical and histopathological features of immune checkpoint inhibitor-related myositis in patients with advanced non-small cell lung cancer].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2022-01-01

回顾性分析7例晚期非小细胞肺癌ICI相关肌炎患者,均为男性,中位年龄64岁。主要表现为肌肉酸痛和乏力,4例伴心肌炎,7例肌酸激酶升高。停用ICI并糖皮质激素治疗后均好转。

要点

  • ICI相关肌炎多表现为肌肉酸痛和四肢乏力,可伴心肌炎。
  • 肌酸激酶普遍升高,抗Ro-52抗体可阳性。
  • 及时停用ICI并启动糖皮质激素治疗可改善预后。

核心结论

  • ICI相关肌炎具有独特的临床病理特征,部分患者合并心血管不良反应,及时识别并停用ICI及糖皮质激素治疗可改善结局。

研究设计与样本

  • 回顾性分析2019年6月至2020年12月广州医科大学附属第一医院呼吸病理中心数据库的7例晚期非小细胞肺癌ICI相关肌炎患者,均为男性,中位年龄64岁(范围42~79岁)。

主要发现

  • 7例患者均接受ICI治疗:帕博利珠单抗3例、信迪利单抗3例、卡瑞利珠单抗1例。
  • 首次用药至肌炎中位时间45天(范围15~176天),症状以肌肉酸痛和四肢乏力为主,4例伴心肌炎。
  • 2例肌肉活检见广泛肌纤维变性坏死和炎症细胞浸润,浸润炎细胞主要为CD8+T细胞和CD68+组织细胞。

临床怎么用

  • 对接受ICI治疗的晚期非小细胞肺癌患者,出现肌肉酸痛、乏力或肌酸激酶升高时应警惕ICI相关肌炎。
  • 一旦怀疑或确诊ICI相关肌炎,应及时停用ICI并启动糖皮质激素治疗。

局限性

  • 回顾性研究,样本量仅7例,均为男性,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinicopathologic features and outcome of myositis in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Methods: The patients diagnosed with immune checkpoint inhibitor-related (ICI) myositis in the database of Respiratory Pathology Center of The First Affiliated Hospital, Guangzhou Medical University from June 2019 to December 2020 were retrospectively analyzed. We reported the muscle histology and main clinical manifestations of the patients in this study. Seven patients with advanced non-small cell lung cancer and ICI related myositis were examined; all of the patients were male, with a median age of 64 (range 42-79) years. Results: All seven patients developed myositis under therapy (three for pembrolizumab, three for sintilimab, and one for camrelizumab). Median delay between ICI initiation and myositis onset was 45 (range 15-176) days. Clinical manifestations were dominated by acute or subacute myalgia and limb weakness. Four patients had evidence of myocarditis. In all of the 7 patients, creatine kinase levels were elevated (median 2 354.4, range 468.6-19 709.2 U/L), while myositis-associated antibodies Ro-52 were positive in four patients. Muscle biopsy showed evident multifocal necrotic myofibers and infiltration of inflammation in two patients. Other patients only showed non-specific endomysial inflammation. Infiltration of inflammation mainly consisted of CD8+ T cells and CD68+ histocytes. After the identification of ICI related myositis, ICI treatment was withdrawn in all patients; 6 patients received corticosteroids therapy. All patients had shown marked clinical improvement. Conclusions: ICI myositis presents with remarkably homogeneous and unique clinicopathologic features, and half of the patients exhibit heightened risk for adverse cardiovascular events, which can be life-threatening if not treated in time. Timely identification of these patients, ICI withdrawal and rapid initiation of corticosteroids therapy can significantly improve patient outcome and/or save patients' lives. 目的: 报道晚期非小细胞肺癌免疫检查点抑制剂(ICI)相关性肌炎的临床病理学特征与治疗转归。 方法: 回顾性分析2019年6月至2020年12月广州医科大学附属第一医院呼吸病理中心数据库的肌肉活检标本及患者的住院病历,纳入7例晚期非小细胞肺癌ICI相关性肌炎,均为男性,中位年龄64岁,年龄范围42~79岁,总结其临床特点。 结果: 7例患者均接受ICI治疗:帕博利珠单抗及信迪利单抗治疗各3例,卡瑞利珠单抗治疗1例。首次用药至发现ICI相关性肌炎的中位时间为45 d,发病时间15~176 d。症状主要表现为肌肉酸痛和四肢乏力,4例患者伴有心肌炎。7例患者均存在肌酸激酶升高,中位值为2 354.4 U/L(范围 468.6~19 709.2 U/L),其中4例出现肌炎相关抗体抗Ro-52 抗体阳性。2例患者肌肉活检观察到广泛肌纤维变性坏死和炎症细胞浸润,其他病例只表现为点状肌纤维坏死或非特异性的肌内膜炎症细胞浸润。浸润的炎细胞主要为CD8+T细胞和CD68+的组织细胞。在明确诊断为ICI相关性肌炎后7例患者均立即停用ICI,其中6例患者口服糖皮质激素治疗,7例患者均好转。 结论: ICI相关性肌炎是一类具有独特的临床病理特征的疾病,部分患者可合并心血管不良反应,如处理不及时可危及生命。及时识别并停用ICI治疗并且采用糖皮质激素治疗可明显改善症状或挽救患者生命。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Jiang JJ, Li YQ, Gu YY, et al. [Clinical and histopathological features of immune checkpoint inhibitor-related myositis in patients with advanced non-small cell lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi. 2022. PMID: 35000305. doi:10.3760/cma.j.cn112147-20210317-00180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。